NY-ESO-1 expression as an inducible chemosensitivity marker

NY-ESO-1 表达作为诱导化疗敏感性标记物

• 批准号: nhmrc : GNT1056577
• 负责人: Dr Sem Liew
• 金额: $ 11.32万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/ny-eso-1-chemosensitivity-marker/1344604
• 关键词: NY; ESO; expression; inducible; chemosensitivity

Immunotherapy is a new concept treatment for lung cancer. Cancer testis antigen (CTA, eg NY-ESO-1) is an immunogenic molecule that was related with poor outcomes, but our recent studies have found that tumours that express NY-ESO-1 are more responsive to chemotherapy. We are also able to induce expression of NY-ESO-1 in cells that do not normally express it using demethylating agents. We aim to determine if we can increase the response to chemotherapy by using these drugs in combination.

免疫治疗是肺癌治疗的新概念。癌症睾丸抗原（CTA，如NY-ESO-1）是一种免疫原性分子，与不良结局相关，但我们最近的研究发现，表达NY-ESO-1的肿瘤对化疗更敏感。我们还能够使用去甲基化剂在通常不表达NY-ESO-1的细胞中诱导NY-ESO-1的表达。我们的目标是确定我们是否可以通过联合使用这些药物来增加对化疗的反应。